Prostate Cancer

>

Latest News

Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.
BCRFS Seen With Apalutamide Combo in Entire High-Risk Prostate Cancer Group

May 5th 2024

Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.

Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.
18F-PSMA-1007 PET/CT Improves Staging Vs MRI in Prostate Cancer

May 3rd 2024

Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.
HIFU Yields Noninferior Outcomes Vs Prostatectomy in Local Prostate Cancer

May 3rd 2024

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.
European Commission Approves Enzalutamide in nmHSPC Subset

April 25th 2024

Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.
Taplin’s Key to a Successful GU Career: “Always Finish” What You Start

March 28th 2024